AstraZeneca PLC (AZN)vsTC Energy Corp (TRP)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
TRP
TC Energy Corp
$64.75
-0.54%
ENERGY · Cap: $67.82B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 291% more annual revenue ($60.44B vs $15.48B). TRP leads profitability with a 22.2% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.52. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
TRP
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
-33.9%
Fair Value
$45.51
Current Price
$64.75
$19.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Strong operational efficiency at 47.5%
Large-cap with strong market position
Keeps 22 of every $100 in revenue as profit
Generating 1.1B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Moderate valuation
Expensive relative to growth rate
Earnings declined 8.5%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TRP
The strongest argument for TRP centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 22.2% and operating margin at 47.5%.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : TRP
The primary concerns for TRP are P/E Ratio, PEG Ratio, EPS Growth. Debt-to-equity of 2.23 is elevated, increasing financial risk.
Key Dynamics to Monitor
TRP carries more volatility with a beta of 0.97 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (62/100 vs 55/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TC Energy Corp
ENERGY · OIL & GAS MIDSTREAM · USA
TC Energy Corporation is an energy infrastructure company in North America. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?